Docetaxel neuropathy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Neurology 1996;46:2-3
Docetaxel (Taxotere) is the second member of a new category of chemotherapeutic antitumor agents with demonstrated efficacy against a variety of tumors that are often refractory to conventional therapy. The diterpene alkaloids, or taxoids as they are known, have a unique mechanism of action. They promote microtubule assembly, leading to the formation of large bundles of disordered microtubules. [1] Because these microtubules are unusually stable, the equilibrium between dissociated tubulin and formed microtubules, which is necessary for mitosis to proceed, is disrupted and the cancer cell dies. This is in contrast to the vinca alkaloids, which induce microtubule disassembly. The first representative of this new class of drugs to be discovered was paclitaxel, originally isolated from the Pacific yew tree, Taxus brevifolia. Paclitaxel was discovered during a screening program in which the investigators were looking for naturally occurring antitumor agents, sponsored by the National Cancer Institute in 1971. [2] Prior to 1993, paclitaxel was referred to as taxol. At that time, Bristol-Myers Squibb (Princeton, NJ) registered the name Taxol, and the generic name, paclitaxel, was approved. Paclitaxel showed early promise as a potentially important new therapy for …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Article
Peripheral neurotoxicity induced by docetaxelP.H.E. Hilkens, J. Verweij, G. Stoter et al.Neurology, January 01, 1996 -
Article
Motor neuropathy due to docetaxel and paclitaxelRonnie J. Freilich, Casilda Balmaceda, Andrew D. Seidman et al.Neurology, July 01, 1996 -
Articles
Vitamin E for prophylaxis against chemotherapy-induced neuropathyA randomized controlled trialA. A. Argyriou, E. Chroni, A. Koutras et al.Neurology, January 10, 2005 -
Article
Transient encephalopathy after paclitaxel (Taxol) infusionJames R. Perry, Ellen Warner et al.Neurology, June 01, 1996